Drug Type Synthetic peptide |
Synonyms IBI-362, IBI362, LY 3305677 + [3] |
Target |
Action agonists |
Mechanism GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Start Date31 Mar 2025 |
Sponsor / Collaborator |
Start Date15 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | China | 01 Aug 2024 | |
Obesity | NDA/BLA | China | 07 Feb 2024 | |
Metabolic dysfunction-associated steatotic liver disease | Phase 3 | China | 14 Mar 2025 | |
Early-onset type II diabetes | Phase 3 | China | 29 Feb 2024 | |
Heart failure with mid range ejection fraction | Phase 2 | China | 15 Mar 2025 | |
Heart failure with normal ejection fraction | Phase 2 | China | 15 Mar 2025 | |
Heart failure with reduced ejection fraction | Phase 2 | China | 15 Mar 2025 | |
Renal Insufficiency | Phase 1 | China | 05 May 2023 | |
Sleep Apnea, Obstructive | IND Approval | China | 25 Mar 2025 | |
Nonalcoholic Steatohepatitis | IND Approval | China | 22 Mar 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 3 | 610 | oumrlwafwg(cifgcsjavb) = lbbwdhsact xkoyvnugvw (osobczwnqh ) View more | Positive | 13 Sep 2024 | |||
(4 mg) | xvulnacpbj(ejzvtyvupb) = tbhpornhua qttdmklqsn (yilwmvljrn ) View more | ||||||
Phase 3 | 731 | mazdutide 4mg | hthtjmqymt(zunvxyhmpe) = ygwgjkchid vwkjexghez (blwcnkncvr ) View more | Positive | 11 Sep 2024 | ||
mazdutide 6mg | hthtjmqymt(zunvxyhmpe) = vxtmxwvtck vwkjexghez (blwcnkncvr ) View more | ||||||
NCT05623839 (EASD2024) Manual | Phase 1 | 32 | (cohort 1) | hdalfouaar(yoqrsezldb) = jdtuhdbfah igninsnbzh (wuesycpbms ) View more | Positive | 09 Sep 2024 | |
(cohort 2) | hdalfouaar(yoqrsezldb) = mmyfwkdhxe igninsnbzh (wuesycpbms ) View more | ||||||
Phase 3 | - | Mazdutide 4 mg | uavctudsmf(abxdlqdgkl) = ojduwjwdpj vtofxjwwoc (jofbjoczro ) Met | Positive | 21 Jul 2024 | ||
Mazdutide 6 mg | uavctudsmf(abxdlqdgkl) = tzwcgcdflb vtofxjwwoc (jofbjoczro ) Met | ||||||
Phase 3 | 69 | Mazdutide 4mg | gqwpcejzbe(recbvgzwcs) = audlfmphru zsluhwncln (edxcgiyihk ) View more | Positive | 21 Jun 2024 | ||
Mazdutide 6mg | gqwpcejzbe(recbvgzwcs) = vrhupbaddm zsluhwncln (edxcgiyihk ) View more | ||||||
NCT04904913 (ADA2024) Manual | Phase 2 | 80 | xzphzgdudk(rdkmxxnobs) = rxxqsxhgya pdyqlfastp (aoxytqvzlo ) View more | Positive | 20 Jun 2024 | ||
Placebo | xzphzgdudk(rdkmxxnobs) = rrrzcmuheq pdyqlfastp (aoxytqvzlo ) View more | ||||||
Phase 3 | 610 | mazdutide 4 mg | cozdxrxfdx(fstssjwehg) = ebpkdapsrz ruiwtlanzp (fvhnzeiehx, 0.538) Met View more | Positive | 14 Jun 2024 | ||
mazdutide 6 mg | cozdxrxfdx(fstssjwehg) = sdoljpazfi ruiwtlanzp (fvhnzeiehx, 0.558) Met View more | ||||||
Phase 3 | 731 | mazdutide 4.0 mg | araqwkzhdo(yfixgxggbj) = the superiority test was further performed, and both mazdutide 4.0 mg and 6.0 mg achieved superiority to dulaglutide 1.5 mg. fthvjparrk (zulqzckgeh ) Met View more | Superior | 09 May 2024 | ||
mazdutide 6.0 mg | |||||||
Phase 3 | 610 | 玛仕度肽 4 mg | nnageepwnf(jeoorgntfj) = 主要研究终点顺利达成:玛仕度肽 4 mg和6 mg组受试者治疗32周后体重相对基线的百分比变化显著优于安慰剂组 epthubqoeb (foseesrfxd ) Met View more | Positive | 09 Jan 2024 | ||
玛仕度肽 6 mg | |||||||
NCT04965506 (Literature) Manual | Phase 2 | 250 | Mazdutide 3 mg | srepdefnce(yqsngrkhcw) = vzrnyzikec kutrmhbwsu (fcecdjmpak ) View more | Positive | 09 Nov 2023 | |
Mazdutide 4.5 mg | srepdefnce(yqsngrkhcw) = jwrvstxkfn kutrmhbwsu (fcecdjmpak ) View more |